August 2021 | Targeted Therapies in Oncology

Adding LuPSMA to Standard Treatment Extends OS, Delays Disease Progression in mCRPC

August 15, 2021

Clinical Articles

Adding the targeted radioligand LuPSMA to standard of care therapy for patients with metastatic castration resistant prostate cancer after androgen receptor pathway inhibition and chemotherapy extended overall survival and delayed disease progression

Genetic Testing Empowers Better Cancer Care, Prevention, and Early Detection

August 13, 2021

Clinical Articles

Today, many community oncology practices routinely employ genetic testing, enabling newly diagnosed patients and their oncologists to make treatment decisions and to formulate preventive strategies based on genetic information.